TransThera
TransThera, officially known as TransThera Sciences, is a pioneering biopharmaceutical company headquartered in China (CN). Founded in 2016, the company has rapidly established itself in the global healthcare landscape, focusing on innovative drug discovery and development, particularly in the fields of oncology and autoimmune diseases. With a commitment to advancing therapeutic solutions, TransThera's core offerings include a range of novel small molecule drugs that target specific disease mechanisms. Their unique approach combines cutting-edge technology with a deep understanding of disease biology, setting them apart in a competitive market. Recognised for its significant contributions to the biopharmaceutical industry, TransThera has achieved notable milestones, including successful clinical trials and strategic partnerships that enhance its market position. As it continues to expand its operational reach, TransThera remains dedicated to improving patient outcomes through transformative therapies.
DitchCarbon Score
How does TransThera's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
TransThera's score of 31 is higher than 96% of the industry. This can give you a sense of how well the company is doing compared to its peers.
TransThera's reported carbon emissions
In 2023, TransThera reported total carbon emissions of approximately 615,000 kg CO2e from Scope 2, 1,500 kg CO2e from Scope 1, and 29,600 kg CO2e from Scope 3. This reflects a notable increase in Scope 1 emissions compared to 2022, where they were about 900 kg CO2e, while Scope 2 emissions decreased from approximately 656,100 kg CO2e to 615,000 kg CO2e. Scope 3 emissions saw a slight reduction from about 29,800 kg CO2e to 29,600 kg CO2e. Looking ahead to 2024, TransThera aims to significantly reduce its carbon footprint, with projected emissions of approximately 100 kg CO2e for Scope 1, 262,200 kg CO2e for Scope 2, and 12,500 kg CO2e for Scope 3. This indicates a strong commitment to reducing emissions across all scopes, particularly in Scope 1 and Scope 2. Despite the absence of specific reduction targets or climate pledges, TransThera's trajectory suggests a proactive approach to climate commitments, aligning with industry standards for emissions reduction. The company is headquartered in China (CN) and is actively working towards minimising its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 900 | 0,000 | 000 |
| Scope 2 | 656,100 | 000,000 | 000,000 |
| Scope 3 | 29,800 | 00,000 | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
TransThera is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
